Raffi, F., Jaeger, H., Quiros-Roldan, E., Albrecht, H., Belonosova, E., Gatell, J. M., . . . Min, S. (2013). Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. The Lancet infectious diseases, 13(11), 927-935. https://doi.org/10.1016/S1473-3099(13)70257-3
Citace podle Chicago (17th ed.)Raffi, François, et al. "Once-daily Dolutegravir Versus Twice-daily Raltegravir in Antiretroviral-naive Adults with HIV-1 Infection (SPRING-2 Study): 96 Week Results from a Randomised, Double-blind, Non-inferiority Trial." The Lancet Infectious Diseases 13, no. 11 (2013): 927-935. https://doi.org/10.1016/S1473-3099(13)70257-3.
Citace podle MLA (9th ed.)Raffi, François, et al. "Once-daily Dolutegravir Versus Twice-daily Raltegravir in Antiretroviral-naive Adults with HIV-1 Infection (SPRING-2 Study): 96 Week Results from a Randomised, Double-blind, Non-inferiority Trial." The Lancet Infectious Diseases, vol. 13, no. 11, 2013, pp. 927-935, https://doi.org/10.1016/S1473-3099(13)70257-3.